{Reference Type}: Journal Article
{Title}: Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation.
{Author}: Hurrell A;Beardmore-Gray A;Duhig K;Webster L;Chappell LC;Shennan AH;
{Journal}: BJOG
{Volume}: 127
{Issue}: 13
{Year}: 12 2020
{Factor}: 7.331
{DOI}: 10.1111/1471-0528.16425
{Abstract}: Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented in clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation. TWEETABLE ABSTRACT: Placental growth factor in pre-eclampsia: evidence and implementation of testing.